Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of FXR expression interference reagent in preparation of anti-hepatic fibrosis drugs

An anti-liver fibrosis, reagent technology, applied in the field of biomedicine to achieve the effect of maintaining integrity

Inactive Publication Date: 2018-05-29
CHINA PHARM UNIV
View PDF13 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the current research is still limited to the role of FXR transcriptional activity in diseases, ignoring the role of FXR expression in the physiological and pathological process of the liver; therefore, it is also limited to the development of reagents that regulate FXR transcriptional activity, while ignoring the intervention of FXR expression Reagents, including drugs and genes (viral and non-viral vectors) and other reagents

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of FXR expression interference reagent in preparation of anti-hepatic fibrosis drugs
  • Application of FXR expression interference reagent in preparation of anti-hepatic fibrosis drugs
  • Application of FXR expression interference reagent in preparation of anti-hepatic fibrosis drugs

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0023] Example 1 The levels of FXR and its downstream signaling molecules are significantly down-regulated in the state of liver fibrosis

[0024] 1 Experimental materials

[0025] Experimental mice (C57BL / 6) were purchased from the Comparative Medicine Center of Yangzhou University;

[0026] CCl 4 Purchased from Shanghai Lingfeng Chemical Reagent Company, mineral oil was purchased from Sigma-Aldrich Company, TrizolRNAiso plus was purchased from Takara Company, reverse transcription kit and SYBR Green were purchased from Applied Biosystems Company, and the primers used were synthesized by Life Company.

[0027] All other biological materials / reagents can be obtained from commercial sources.

[0028] 2 Experimental methods

[0029] 2.1 Establishment of mouse liver fibrosis model

[0030] After the animals were adaptively fed for one week, the mice were randomly divided into 2 groups, 8 in each group, 16 in total. The control group and the model group were respectively, and...

Embodiment 2

[0049] Example 2 Injecting mice with FXR adenovirus can significantly improve the symptoms of liver fibrosis

[0050] 1 Experimental materials

[0051] The adenovirus carrying FXR (Ad-FXR) was donated by Professor Frank J Gonzalez of the NIH Center in the United States and amplified by Bailingwei Biotechnology Co., Ltd. The control adenovirus (Ad-Ctrl) was designed, synthesized and amplified by the company;

[0052] Experimental mice were purchased from the Comparative Medicine Center of Yangzhou University;

[0053] Anti-FXR antibody was purchased from Abcam Company, and anti-GAPDH antibody was purchased from Bioworld Company.

[0054] All the other experimental materials are the same as in Example 1.

[0055] 2 Experimental methods

[0056] 2.1 Adenovirus transfection of mice

[0057] After the animals were adaptively fed for one week, the mice were randomly divided into 4 groups, 10 in each group, 40 in total. They were blank control group, FXR Adenovirus group, model ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to the field of biomedicine. The present invention provides application of a farnesoid X receptor (FXR) expression interference reagent in preparation of anti-hepatic fibrosis drugs. Specifically, the present invention relates to application of FXR for treatment of hepatic fibrosis, by tail intravenous injection of the farnesoid X receptor (FXR) expression interference reagent (namely, an adenovirus carrying FXR plasmid) to mice, the expression level of the FXR in hepatocytes is significantly increased, CCl4-induced hepatic fibrosis can be significantly countered,hepatocyte morphology and structural integrity can be maintained, and serum transaminase level can be reduced. A new approach for clinical treatment of liver diseases especially hepatic fibrosis is provided.

Description

technical field [0001] The present invention relates to the field of biomedicine. Specifically, the present invention belongs to gene medicine in the field of biopharmaceuticals, and in particular relates to a gene therapy drug against liver fibrosis, that is, using a recombinant adenovirus carrying farnesoid X receptor (FXR) in the preparation of liver Application in drugs for the prevention and treatment of fibrotic diseases. technical background [0002] The incidence of liver diseases, especially viral hepatitis, fatty liver disease, liver fibrosis and liver cancer, remains high worldwide. For example, the incidence rate of NAFLD among ordinary adults in Europe and America is 20-33%, and the incidence rate among obese people reaches 60-90%; the prevalence rate of ordinary adults in China is about 15% (Fan J G, Farrell G C. non-alcoholic fatty liver disease in China. Journal of Hepatology, 2009, 50(1): 204-10.). Liver fibrosis (Fibrosis) is a pathological state, which ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K48/00A61P1/16
CPCA61K48/0008
Inventor 郝海平王洪王广基周济宇郭怡彤黄宁宁
Owner CHINA PHARM UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com